CORRECTION OF IMMATERIAL ERRORS - Schedule of unaudited condensed consolidated interim statement of operations (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2025 |
Sep. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
| Business development expenses | $ 144,015 | $ 180,000 | $ 1,841,982 | $ 360,000 | ||||
| Consulting fees | 1,124,862 | 390,350 | 4,263,195 | 998,364 | ||||
| Research and development expenses | 83,263 | 255,479 | 1,027,203 | 0 | ||||
| Total operating expenses | 4,053,852 | 1,879,553 | 15,333,932 | 4,301,083 | ||||
| Grant income | 24,000 | 40,000 | 163,723 | 0 | ||||
| Net loss | (4,269,131) | (2,653,107) | $ (16,543,616) | $ (7,908,777) | ||||
| As corrected [Member] | ||||||||
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
| Business development expenses | $ 472,500 | $ 376,125 | $ 376,125 | $ 848,625 | ||||
| Consulting fees | 100,000 | 100,000 | ||||||
| Research and development expenses | 255,479 | 255,479 | ||||||
| Grant income | 40,000 | |||||||
| Net loss | $ (2,422,410) | $ (1,934,427) | $ (2,653,107) | $ (4,587,534) | $ (7,009,944) | |||
| Loss per share | $ (0.12) | $ (0.09) | $ (0.13) | $ (0.23) | $ (0.34) | |||
| Correction of immaterial errros [Member] | As previously reported [Member] | ||||||||
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
| Business development expenses | $ 194,736 | $ 206,000 | $ 386,000 | $ 580,736 | ||||
| Consulting fees | 423,490 | 1,189,450 | ||||||
| Research and development expenses | 441,992 | $ 0 | ||||||
| Total operating expenses | 1,980,953 | 2,056,672 | 1,624,074 | 3,680,746 | 5,661,699 | |||
| Grant income | 0 | |||||||
| Net loss | $ (2,049,910) | $ (1,813,781) | $ (2,437,628) | $ (4,211,409) | $ (6,261,319) | |||
| Loss per share | $ (0.09) | $ (0.09) | $ (0.12) | $ (0.21) | $ (0.3) | |||
| Correction of immaterial errros [Member] | Adjustment [Member] | ||||||||
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
| Business development expenses | $ 472,500 | $ 376,125 | $ 376,125 | $ 848,625 | ||||
| Consulting fees | (100,000) | (100,000) | ||||||
| Research and development expenses | $ 255,479 | (255,479) | $ 255,479 | |||||
| Total operating expenses | 372,500 | 120,646 | 255,479 | 376,125 | 748,625 | |||
| Grant income | 40,000 | |||||||
| Net loss | $ (372,500) | $ (120,646) | $ (215,479) | $ (376,125) | $ (748,625) | |||
| Loss per share | $ (0.03) | $ 0 | $ (0.01) | $ (0.02) | $ (0.04) | |||
| Correction of immaterial errros [Member] | As corrected [Member] | ||||||||
| Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
| Business development expenses | $ 667,236 | $ 582,125 | $ 762,125 | $ 1,429,361 | ||||
| Consulting fees | 323,490 | 1,089,450 | ||||||
| Research and development expenses | 186,513 | $ 255,479 | ||||||
| Total operating expenses | 2,353,453 | 2,177,318 | 1,879,553 | 4,056,871 | 6,410,324 | |||
| Grant income | 40,000 | |||||||
| Net loss | $ (2,422,410) | $ (1,934,427) | $ (2,653,107) | $ (4,587,534) | $ (7,009,944) | |||
| Loss per share | $ (0.12) | $ (0.09) | $ (0.13) | $ (0.23) | $ (0.34) | |||